Three CXCR1/2 antagonists, namely the small chemical entities, reparixin (formerly known as repertaxin) [138], SX-682 [38,139] and navarixin (MK-7123) [140] have recently entered the clinical arena of adjunctive therapy of cancer. Here, CXCR1 is linked to cancer.